DK1200580T3 - Modulering af oligonukleotid-CpG-medieret immunstimulering ved positionel modifikation - Google Patents

Modulering af oligonukleotid-CpG-medieret immunstimulering ved positionel modifikation

Info

Publication number: DK1200580T3
Authority: DK; Denmark
Prior art keywords: modulation; mediated immune; immune stimulation; positional modification; oligonucleotide cpg
Prior art date: 1999-08-13

Application number

DK00955527T

Other languages

Danish (da)

English (en)

Inventor

Sudhir Agrawal

Original Assignee

Hybridon Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-13

Filing date

2000-08-14

Publication date

2005-04-11

2000-08-14 Application filed by Hybridon Inc filed Critical Hybridon Inc

2005-04-11 Application granted granted Critical

2005-04-11 Publication of DK1200580T3 publication Critical patent/DK1200580T3/da

Links

108091034117 Oligonucleotide Proteins 0.000 title abstract 2
230000001404 mediated effect Effects 0.000 title 1
230000004048 modification Effects 0.000 title 1
238000012986 modification Methods 0.000 title 1
230000000638 stimulation Effects 0.000 title 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
230000000692 anti-sense effect Effects 0.000 abstract 1
230000003247 decreasing effect Effects 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
230000003308 immunostimulating effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Genetics & Genomics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Biochemistry (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Virology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Transplantation (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)

DK00955527T 1999-08-13 2000-08-14 Modulering af oligonukleotid-CpG-medieret immunstimulering ved positionel modifikation DK1200580T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US14879899P	1999-08-13	1999-08-13
EP00955527A EP1200580B1 (en)	1999-08-13	2000-08-14	MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
PCT/US2000/022284 WO2001012804A2 (en)	1999-08-13	2000-08-14	MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES

Publications (1)

Publication Number	Publication Date
DK1200580T3 true DK1200580T3 (da)	2005-04-11

Family

ID=22527436

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK00955527T DK1200580T3 (da)	1999-08-13	2000-08-14	Modulering af oligonukleotid-CpG-medieret immunstimulering ved positionel modifikation

Country Status (13)

Country	Link
US (1)	US6476000B1 (pt)
EP (2)	EP2314693A3 (pt)
JP (2)	JP5268214B2 (pt)
KR (1)	KR100651294B1 (pt)
AT (1)	ATE286534T1 (pt)
AU (2)	AU783745B2 (pt)
CA (2)	CA2381993A1 (pt)
DE (1)	DE60017259T2 (pt)
DK (1)	DK1200580T3 (pt)
ES (1)	ES2233426T3 (pt)
MX (1)	MXPA02001610A (pt)
PT (1)	PT1200580E (pt)
WO (1)	WO2001012804A2 (pt)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6239116B1 (en)	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US20030026782A1 (en)	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US20030022854A1 (en)	1998-06-25	2003-01-30	Dow Steven W.	Vaccines using nucleic acid-lipid complexes
US6558951B1 (en) *	1999-02-11	2003-05-06	3M Innovative Properties Company	Maturation of dendritic cells with immune response modifying compounds
US6977245B2 (en)	1999-04-12	2005-12-20	The United States Of America As Represented By The Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
US6949520B1 (en)	1999-09-27	2005-09-27	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
EP1322655B1 (en)	2000-01-14	2007-11-14	The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services	Oligodeoxynucleotide and its use to induce an immune response
DE60109916T2 (de)	2000-05-01	2006-01-19	Hybridon, Inc., Cambridge	MODULATION EINER OLIGONUKLEOTID- CpG-VERMITTELTEN IMMUNSTIMULATION DURCH POSITIONELLE MODIFIKATION VON NUKLEOSIDEN
CA2598144A1 (en) *	2000-12-08	2006-08-31	3M Innovative Properties Company	Compositions and methods for targeted delivery of immune response modifiers
US7176296B2 (en)	2001-04-30	2007-02-13	Idera Pharmaceuticals, Inc.	Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US7105495B2 (en)	2001-04-30	2006-09-12	Idera Pharmaceuticals, Inc.	Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
DK1404873T3 (da)	2001-06-21	2013-08-05	Dynavax Tech Corp	Kimæriske immunmodulatoriske forbindelser og fremgangsmåder til anvendelse deraf
US7785610B2 (en) *	2001-06-21	2010-08-31	Dynavax Technologies Corporation	Chimeric immunomodulatory compounds and methods of using the same—III
US20030133988A1 (en) *	2001-08-07	2003-07-17	Fearon Karen L.	Immunomodulatory compositions, formulations, and methods for use thereof
AU2002361468A1 (en)	2001-08-14	2003-03-18	The Government Of The United States Of America As Represented By The Secretary Of Health And Human S	Method for rapid generation of mature dendritic cells
US7276489B2 (en)	2002-10-24	2007-10-02	Idera Pharmaceuticals, Inc.	Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
US20040014779A1 (en) *	2001-11-16	2004-01-22	3M Innovative Properties Company	Methods and compositions related to IRM compounds and toll-like recptor pathways
US7615227B2 (en)	2001-12-20	2009-11-10	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of CpG oligodeoxynucleotides to induce angiogenesis
CA2365732A1 (en) *	2001-12-20	2003-06-20	Ibm Canada Limited-Ibm Canada Limitee	Testing measurements
EP1474432A1 (en)	2002-02-04	2004-11-10	Biomira Inc.	Immunostimulatory, covalently lipidated oligonucleotides
SI1478327T1 (sl) *	2002-02-22	2015-08-31	Meda Ab	Metoda za zmanjšanje in zdravljenje imunosupresije, inducirane z UV-B
CA2388049A1 (en)	2002-05-30	2003-11-30	Immunotech S.A.	Immunostimulatory oligonucleotides and uses thereof
CN1671412B (zh)	2002-08-15	2010-05-26	3M创新有限公司	免疫刺激组合物及刺激免疫反应的方法
AR040996A1 (es)	2002-08-19	2005-04-27	Coley Pharm Group Inc	Acidos nucleicos inmunoestimuladores
JP2006512927A (ja)	2002-12-11	2006-04-20	コーリーファーマシューティカルグループ，インコーポレイテッド	５’ｃｐｇ核酸およびその使用方法
AU2003287316A1 (en) *	2002-12-11	2004-06-30	3M Innovative Properties Company	Assays relating to toll-like receptor activity
AU2003287324A1 (en) *	2002-12-11	2004-06-30	3M Innovative Properties Company	Gene expression systems and recombinant cell lines
US8158768B2 (en)	2002-12-23	2012-04-17	Dynavax Technologies Corporation	Immunostimulatory sequence oligonucleotides and methods of using the same
SG2011035342A (en)	2002-12-23	2016-12-29	Dynavax Tech Corp	Immunostimulatory sequence oligonucleotides and methods of using the same
WO2004060319A2 (en)	2002-12-30	2004-07-22	3M Innovative Properties Company	Immunostimulatory combinations
WO2004064782A2 (en)	2003-01-16	2004-08-05	Hybridon, Inc.	Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
US7354907B2 (en) *	2003-02-07	2008-04-08	Idera Pharmaceuticals, Inc.	Short immunomodulatory oligonucleotides
EP1592302A4 (en) *	2003-02-13	2007-04-25	3M Innovative Properties Co	METHODS AND COMPOSITIONS ASSOCIATED WITH IMMUNE RESPONSE MODIFIER COMPOUNDS AND TOLL-LIKE RECEPTOR 8
ES2385933T3 (es)	2003-02-20	2012-08-03	University Of Connecticut Health Center	Métodos para la producción de complejos de moléculas antígenas de alfa (2) macroglobulina.
US7485432B2 (en) *	2003-02-27	2009-02-03	3M Innovative Properties Company	Selective modulation of TLR-mediated biological activity
KR100681470B1 (ko) *	2003-03-03	2007-02-12	연세대학교 산학협력단	면역반응 증진용 올리고뉴크레오타이드
JP2006519866A (ja)	2003-03-04	2006-08-31	スリーエムイノベイティブプロパティズカンパニー	Ｕｖ誘発性の表皮の新形成の予防的治療
MXPA05009694A (es) *	2003-03-13	2005-10-20	3M Innovative Properties Co	Metodos para mejorar la calidad de la piel.
WO2004080292A2 (en)	2003-03-13	2004-09-23	3M Innovative Properties Company	Method of tattoo removal
US20040192585A1 (en)	2003-03-25	2004-09-30	3M Innovative Properties Company	Treatment for basal cell carcinoma
US20040265351A1 (en) *	2003-04-10	2004-12-30	Miller Richard L.	Methods and compositions for enhancing immune response
US20040202720A1 (en) *	2003-04-10	2004-10-14	3M Innovative Properties Company	Delivery of immune response modifier compounds using metal-containing particulate support materials
CA2526212C (en)	2003-05-16	2013-08-27	Hybridon, Inc.	Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
CA2532926A1 (en)	2003-07-15	2005-02-03	Hybridon, Inc.	Combined use of immunostimulatory oligonucleotides and cytokines or radiation
MXPA06001004A (es) *	2003-07-31	2006-04-27	3M Innovative Properties Co	Composiciones para encapsulacion y liberacion controlada.
JP2007501251A (ja) *	2003-08-05	2007-01-25	スリーエムイノベイティブプロパティズカンパニー	免疫応答調節剤化合物を使用する感染予防
CA2535120A1 (en)	2003-08-12	2005-03-03	3M Innovative Properties Company	Hydroxylamine substituted imidazo-containing compounds
US20050048072A1 (en) *	2003-08-25	2005-03-03	3M Innovative Properties Company	Immunostimulatory combinations and treatments
WO2005020912A2 (en)	2003-08-25	2005-03-10	3M Innovative Properties Company	Delivery of immune response modifier compounds
KR101106812B1 (ko)	2003-08-27	2012-01-19	쓰리엠 이노베이티브 프로퍼티즈 컴파니	아릴옥시 및 아릴알킬렌옥시 치환된 이미다조퀴놀린
US20060216333A1 (en) *	2003-09-02	2006-09-28	Miller Richard L	Methods related to the treatment of mucosal associated conditions
AU2004270201A1 (en) *	2003-09-05	2005-03-17	3M Innovative Properties Company	Treatment for CD5+ B cell lymphoma
WO2005030259A2 (en)	2003-09-25	2005-04-07	Coley Pharmaceutical Group, Inc.	Nucleic acid-lipophilic conjugates
US7544697B2 (en)	2003-10-03	2009-06-09	Coley Pharmaceutical Group, Inc.	Pyrazolopyridines and analogs thereof
WO2005032484A2 (en)	2003-10-03	2005-04-14	3M Innovative Properties Company	Alkoxy substituted imidazoquinolines
NZ546275A (en)	2003-10-30	2009-05-31	Coley Pharm Gmbh	C-class oligonucleotides analogs with enhanced immunostimulatory potency
US20050096259A1 (en) *	2003-10-31	2005-05-05	3M Innovative Properties Company	Neutrophil activation by immune response modifier compounds
EP1682544A4 (en)	2003-11-14	2009-05-06	3M Innovative Properties Co	HYDROXYLAMINE SUBSTITUTED IMIDAZO RING COMPOUNDS
CN1906193A (zh)	2003-11-14	2007-01-31	3M创新有限公司	肟取代的咪唑环化合物
SG148201A1 (en)	2003-11-25	2008-12-31	3M Innovative Properties Co	Substituted imidazo ring systems and methods
US20050226878A1 (en) *	2003-12-02	2005-10-13	3M Innovative Properties Company	Therapeutic combinations and methods including IRM compounds
EP1689361A4 (en) *	2003-12-02	2009-06-17	3M Innovative Properties Co	THERAPEUTIC COMBINATIONS AND PROCESSES WITH IRM COMPOUNDS
US7713535B2 (en)	2003-12-08	2010-05-11	Idera Pharmaceuticals, Inc.	Modulation of immunostimulatory properties by small oligonucleotide-based compounds
US8802853B2 (en)	2003-12-29	2014-08-12	3M Innovative Properties Company	Arylalkenyl and arylalkynyl substituted imidazoquinolines
US20050239735A1 (en) *	2003-12-30	2005-10-27	3M Innovative Properties Company	Enhancement of immune responses
WO2005066169A2 (en)	2003-12-30	2005-07-21	3M Innovative Properties Company	Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
CA2559863A1 (en)	2004-03-24	2005-10-13	3M Innovative Properties Company	Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
EP1755665A4 (en) *	2004-04-28	2010-03-03	3M Innovative Properties Co	COMPOSITIONS AND METHODS FOR MUCOSAL VACCINATION
US20050267145A1 (en) *	2004-05-28	2005-12-01	Merrill Bryon A	Treatment for lung cancer
US20080154210A1 (en)	2004-05-28	2008-06-26	Oryxe	Mixture for Transdermal Delivery of Low and High Molecular Weight Compounds
AU2005326144A1 (en) *	2004-06-08	2006-08-03	Coley Pharmaceutical Gmbh	Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist
US8017779B2 (en)	2004-06-15	2011-09-13	3M Innovative Properties Company	Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006065280A2 (en)	2004-06-18	2006-06-22	3M Innovative Properties Company	Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
US8026366B2 (en)	2004-06-18	2011-09-27	3M Innovative Properties Company	Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US7897609B2 (en)	2004-06-18	2011-03-01	3M Innovative Properties Company	Aryl substituted imidazonaphthyridines
EP1786450A4 (en) *	2004-08-27	2009-11-11	3M Innovative Properties Co	HIV IMMUNOSTIMATORY COMPOSITIONS
WO2006042254A2 (en) *	2004-10-08	2006-04-20	3M Innovative Properties Company	Adjuvant for dna vaccines
US7943609B2 (en)	2004-12-30	2011-05-17	3M Innovative Proprerties Company	Chiral fused [1,2]imidazo[4,5-C] ring compounds
JP5313502B2 (ja)	2004-12-30	2013-10-09	スリーエムイノベイティブプロパティズカンパニー	置換キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
EP1830876B1 (en) *	2004-12-30	2015-04-08	Meda AB	Use of imiquimod for the treatment of cutaneous metastases derived from a breast cancer tumor
CA2597092A1 (en)	2005-02-04	2006-08-10	Coley Pharmaceutical Group, Inc.	Aqueous gel formulations containing immune reponse modifiers
WO2006086634A2 (en)	2005-02-11	2006-08-17	Coley Pharmaceutical Group, Inc.	Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
US7943636B2 (en)	2005-04-01	2011-05-17	3M Innovative Properties Company	1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
WO2006107853A2 (en)	2005-04-01	2006-10-12	Coley Pharmaceutical Group, Inc.	Pyrazolopyridine-1,4-diamines and analogs thereof
CN104278037B (zh) *	2005-10-12	2020-09-15	艾德拉药物股份有限公司	基于变异应答调制Toll样受体的免疫调节寡核苷酸(IRO)化合物
US7776834B2 (en) *	2005-11-07	2010-08-17	Idera Pharmaceuticals, Inc.	Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
US7470674B2 (en)	2005-11-07	2008-12-30	Idera Pharmaceuticals, Inc.	Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
CA2628306C (en)	2005-11-07	2014-06-17	Sudhir Agrawal	Immunostimulatory oligonucleotide-based compounds with glycerol-linked dinucleotides and modified guanosines at cpg and uses thereof
WO2007100634A2 (en) *	2006-02-22	2007-09-07	3M Innovative Properties Company	Immune response modifier conjugates
US7906506B2 (en)	2006-07-12	2011-03-15	3M Innovative Properties Company	Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
PT2078080E (pt)	2006-09-27	2015-09-18	Coley Pharm Gmbh	Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada
US20080149123A1 (en)	2006-12-22	2008-06-26	Mckay William D	Particulate material dispensing hairbrush with combination bristles
AU2008286735A1 (en) *	2007-08-15	2009-02-19	Idera Pharmaceuticals, Inc.	Toll like receptor modulators
MX2011003625A (es) *	2008-10-06	2011-05-31	Idera Pharmaceuticals Inc	Uso de inhibidores de receptores tipo toll en la prevencion y tratamiento de hipercolesterolemia e hiperlipidemia y enfermedades relacionadas con esto.
EP2451974A2 (en) *	2009-07-08	2012-05-16	Idera Pharmaceuticals, Inc.	Oligonucleotide-based compounds as inhibitors of toll-like receptors
US20110033515A1 (en) *	2009-08-04	2011-02-10	Rst Implanted Cell Technology	Tissue contacting material
EP2640420B1 (en)	2010-11-19	2018-08-15	Idera Pharmaceuticals, Inc.	Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
AU2012261959B2 (en)	2011-06-03	2015-12-03	Solventum Intellectual Properties Company	Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom
WO2012167088A1 (en)	2011-06-03	2012-12-06	3M Innovative Properties Company	Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
US20130023736A1 (en)	2011-07-21	2013-01-24	Stanley Dale Harpstead	Systems for drug delivery and monitoring
WO2015011254A1 (en)	2013-07-26	2015-01-29	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of bacterial infections
WO2016180852A1 (en)	2015-05-12	2016-11-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for preparing antigen-specific t cells from an umbilical cord blood sample
CN119908979A (zh)	2015-09-17	2025-05-02	Jrx生物技术有限公司	改善皮肤的水合作用或润湿作用的方法
EP3357507A4 (en) *	2015-09-30	2019-05-29	Shionogi & Co., Ltd	NUCLEIC ACID DERIVATIVE WITH IMMUNOSTIMULATING EFFECT
US10940201B2 (en)	2015-09-30	2021-03-09	Shionogi & Co., Ltd.	Nucleic acid derivative having immunostimulatory activity
WO2017059280A1 (en)	2015-10-02	2017-04-06	The University Of North Carolina At Chapel Hill	Novel pan-tam inhibitors and mer/axl dual inhibitors
US10463686B2 (en)	2016-09-15	2019-11-05	Idera Pharmaceuticals, Inc.	Immune modulation with TLR9 agonists for cancer treatment
SG11201908059YA (en) *	2017-03-29	2019-10-30	Shionogi & Co	Nucleic acid derivative having immunostimulatory activity
EP3759129A1 (en)	2018-02-28	2021-01-06	Pfizer Inc	Il-15 variants and uses thereof
TWI793325B (zh)	2018-05-23	2023-02-21	美商輝瑞大藥廠	對cd3具特異性之抗體及其用途
CN113286634A (zh)	2018-05-23	2021-08-20	辉瑞公司	对gucy2c特异性的抗体及其用途
WO2020128893A1 (en)	2018-12-21	2020-06-25	Pfizer Inc.	Combination treatments of cancer comprising a tlr agonist
IL293926A (en)	2019-12-17	2022-08-01	Pfizer	Antibodies specific for cd47, pd-l1, and uses thereof
PH12023550139A1 (en)	2020-07-17	2024-06-24	Pfizer	Therapeutic antibodies and their uses

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5149798A (en)	1989-04-06	1992-09-22	Worcester Foundation For Experimental Biology	Process for synthesizing oligonucleotides and their analogs adaptable to large scale syntheses
US6153595A (en) *	1990-08-16	2000-11-28	Isis Pharmaceuticals Inc.	Composition and method for treatment of CMV infections
JPH06511387A (ja) *	1991-12-24	1994-12-22	アイシス・ファーマシューティカルス・インコーポレーテッド	β−アミロイド調節のための組成物および方法
US6235723B1 (en) *	1992-03-16	2001-05-22	Isis Pharmaceuticals , Inc.	Antisense oligonucleotide modulation of human protein kinase C-δ expression
US6207646B1 (en) *	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US5591721A (en) *	1994-10-25	1997-01-07	Hybridon, Inc.	Method of down-regulating gene expression
US5968909A (en) *	1995-08-04	1999-10-19	Hybridon, Inc.	Method of modulating gene expression with reduced immunostimulatory response
US5652356A (en) *	1995-08-17	1997-07-29	Hybridon, Inc.	Inverted chimeric and hybrid oligonucleotides
US5856462A (en) *	1996-09-10	1999-01-05	Hybridon Incorporated	Oligonucleotides having modified CpG dinucleosides
US5886165A (en) *	1996-09-24	1999-03-23	Hybridon, Inc.	Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments
JP2001514884A (ja) *	1997-08-19	2001-09-18	ハイブリドン・インク	新規なｈｉｖ特異的合成オリゴヌクレオチド及びその使用方法
US6228642B1 (en) *	1998-10-05	2001-05-08	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression

2000
- 2000-08-14 CA CA002381993A patent/CA2381993A1/en not_active Abandoned
- 2000-08-14 WO PCT/US2000/022284 patent/WO2001012804A2/en not_active Ceased
- 2000-08-14 EP EP10010051A patent/EP2314693A3/en not_active Withdrawn
- 2000-08-14 EP EP00955527A patent/EP1200580B1/en not_active Expired - Lifetime
- 2000-08-14 DK DK00955527T patent/DK1200580T3/da active
- 2000-08-14 DE DE60017259T patent/DE60017259T2/de not_active Expired - Lifetime
- 2000-08-14 US US09/639,250 patent/US6476000B1/en not_active Expired - Lifetime
- 2000-08-14 AU AU67720/00A patent/AU783745B2/en not_active Ceased
- 2000-08-14 ES ES00955527T patent/ES2233426T3/es not_active Expired - Lifetime
- 2000-08-14 PT PT00955527T patent/PT1200580E/pt unknown
- 2000-08-14 CA CA2784789A patent/CA2784789A1/en not_active Abandoned
- 2000-08-14 AT AT00955527T patent/ATE286534T1/de active
- 2000-08-14 JP JP2001517689A patent/JP5268214B2/ja not_active Expired - Fee Related
- 2000-08-14 MX MXPA02001610A patent/MXPA02001610A/es active IP Right Grant
- 2000-08-14 KR KR1020027001695A patent/KR100651294B1/ko not_active Expired - Fee Related
2005
- 2005-12-12 AU AU2005242217A patent/AU2005242217A1/en not_active Withdrawn
2010
- 2010-09-22 JP JP2010212544A patent/JP2011019527A/ja active Pending

Also Published As

Publication number	Publication date
WO2001012804A2 (en)	2001-02-22
AU2005242217A1 (en)	2006-01-12
DE60017259D1 (de)	2005-02-10
EP1200580B1 (en)	2005-01-05
KR100651294B1 (ko)	2006-11-28
WO2001012804A3 (en)	2001-09-07
US6476000B1 (en)	2002-11-05
CA2784789A1 (en)	2001-02-22
EP1200580A2 (en)	2002-05-02
CA2381993A1 (en)	2001-02-22
ES2233426T3 (es)	2005-06-16
JP5268214B2 (ja)	2013-08-21
PT1200580E (pt)	2005-03-31
DE60017259T2 (de)	2005-12-08
JP2003526628A (ja)	2003-09-09
KR20020059586A (ko)	2002-07-13
ATE286534T1 (de)	2005-01-15
MXPA02001610A (es)	2003-07-21
EP2314693A2 (en)	2011-04-27
AU783745B2 (en)	2005-12-01
AU6772000A (en)	2001-03-13
EP2314693A3 (en)	2012-11-28
JP2011019527A (ja)	2011-02-03

Publication	Publication Date	Title
DK1200580T3 (da)	2005-04-11	Modulering af oligonukleotid-CpG-medieret immunstimulering ved positionel modifikation
DK1278761T3 (da)	2005-08-08	Modulering af oligonukleotid CpG-medieret immunstimulering ved hjælp af positionsmodificering af nukleosider
WO2001055370A3 (en)	2002-01-17	MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
DK1117672T3 (da)	2009-12-07	Antisense-modulation af survivin-ekpression
DK1250455T3 (da)	2008-08-18	Antisense-inhibering af PTP1B-ekspression
WO2002036743A3 (en)	2003-01-16	Antisense modulation of calreticulin expression
DE60143901D1 (de)	2011-03-03	Antisense-modulation der clusterinexpression
WO2003011887A3 (en)	2003-04-24	Antisense modulation of apolipoprotein b expression
EP1131465A4 (en)	2004-05-26	ANTISENSE MODULATION OF INTERLEUKIN EXPRESSION 15
EP1417351A4 (en)	2005-06-01	ANTISENSE MODULATION OF THE EXPRESSION OF APOLIPOPROTEIN (A)
EP2199299A3 (en)	2010-10-20	Antisense modulation of survivin expression
WO2003046132A3 (en)	2003-08-07	Antisense modulation of myd88 expression
WO2003053341A3 (en)	2005-05-26	Antisense modulation of ship-1 expression
WO2001083513A3 (en)	2002-05-23	Antisense modulation of inhibitor of dna binding-1 expression
WO2002095053A3 (en)	2003-05-01	Antisense modulation of src-c expression
EP1165145A4 (en)	2003-03-05	ANTISENSE MODULATION OF THE MDMX EXPRESSION
WO2003052062A3 (en)	2005-03-10	Antisense modulation of cd36l1 expression
WO2003057847A8 (en)	2004-01-15	METHODS AND MATERIALS FOR MODULATING ENaC-BETA
WO2003044163A3 (en)	2004-04-15	Antisense modulation of toll-like receptor 4 expression
WO2003053342A3 (en)	2004-03-04	Antisense modulation of cd81 expression
WO2002055535A3 (en)	2002-10-31	Antisense modulation of cytohesin-1 expression
WO2002097108A3 (en)	2004-06-03	Antisense modulation of dual specific phosphatase 5 expression
WO2003030617A3 (en)	2003-12-04	Antisense modulation of creb expression
EP1496121A3 (en)	2005-02-09	Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
WO2003038050A3 (en)	2004-04-01	Antisense modulation of phospholipase a2 group v expression